UBS upgrades Medtronic stock citing confidence in diabetes segment

Published 15/08/2024, 08:08
UBS upgrades Medtronic stock citing confidence in diabetes segment

On Thursday, Medtronic , Inc. (NYSE:MDT) stock received an upgrade in its rating by a UBS analyst from Sell to Neutral. The firm also increased its price target for the company's shares from $76.00 to $90.00. The revision is attributed to a renewed confidence in the sustainability of Medtronic's recent turnaround in its Diabetes business segment.

The Diabetes division, which accounts for nearly 10% of Medtronic's sales, has been identified as a key driver for the company's revenue growth. The analyst's improved outlook on this segment led to an increase in the fiscal year 2026 and 2027 sales and earnings per share (EPS) estimates. Specifically, there is an anticipated increase of 60 basis points in sales and 120 basis points in EPS for both fiscal years.

The upgrade reflects the belief that the company's performance in the Diabetes market could help balance potential weaknesses in other areas of the business, such as Surgical and Cardiac Ablation Solutions. The analyst's expectations for Medtronic's sales growth stand at approximately 4% in fiscal year 2026, which aligns with investor forecasts and is slightly below the consensus estimate of around 5%.

The positive shift in Medtronic's stock rating and the rise in the price target come as a result of the detailed analysis of the company's growth prospects, particularly in the Diabetes sector. The UBS analyst's comments underscore the importance of this segment to Medtronic's overall financial health and growth trajectory.

InvestingPro Insights

Following the UBS analyst's upgrade of Medtronic, Inc. (NYSE:MDT), the InvestingPro platform offers additional insights that could be pertinent for investors considering the company's stock. With a solid market capitalization of $104.84 billion and a P/E ratio standing at 21.96 for the last twelve months as of Q4 2024, Medtronic appears to be maintaining a stable financial position. The company's revenue growth over the same period is modest at 3.64%, reflecting a consistent upward trend.

InvestingPro Tips highlight that Medtronic has been actively engaging in share buybacks, which could be a sign of management's confidence in the company's value. Additionally, the company's longstanding history of dividend payments, with dividends raised for 10 consecutive years and maintained for 48 years, offers investors a degree of reliability in terms of shareholder returns. Furthermore, Medtronic's low price volatility may appeal to investors seeking stability in their portfolios.

For those interested in a deeper analysis, InvestingPro provides several more tips that could guide investment decisions. To explore these additional insights, visit https://www.investing.com/pro/MDT.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.